HIV behind bars: human immunodeficiency virus cluster analysis and drug resistance in a reference correctional unit from southern Brazil.

Isabel M Prellwitz, Brunna M Alves, Maria Letícia R Ikeda, Daniele Kuhleis, Pedro D Picon, Carla A Jarczewski, Marta R Osório, Alexandra Sánchez, Héctor N Seuánez, Bernard Larouzé, Marcelo A Soares, Esmeralda A Soares
Author Information
  1. Isabel M Prellwitz: Programa de Genética, Instituto Nacional de Câncer, Rio de Janeiro, Brazil.

Abstract

People deprived of liberty in prisons are at higher risk of infection by the human immunodeficiency virus (HIV) due to their increased exposure through intravenous drug use, unprotected sexual activity, tattooing in prison and blood exposure in fights and rebellions. Yet, the contribution of intramural HIV transmission to the epidemic is scarcely known, especially in low- and middle-income settings. In this study, we surveyed 1,667 inmates incarcerated at Presídio Central de Porto Alegre, located in southern Brazil, for HIV infection and molecular characterization. The HIV seroprevalence was 6.6% (110/1,667). Further analyses were carried out on 40 HIV-seropositive inmates to assess HIV transmission clusters and drug resistance within the facility with the use of molecular and phylogenetic techniques. The molecular epidemiology of HIV-1 subtypes observed was similar to the one reported for the general population in southern Brazil, with the predominance of HIV-1 subtypes C, B, CRF31_BC and unique BC recombinants. In particular, the high rate (24%) of URF_BC found here may reflect multiple exposures of the population investigated to HIV infection. We failed to find HIV-infected inmates sharing transmission clusters with each other. Importantly, the analysis of HIV-1 pol genomic fragments evidenced high rates of HIV primary and secondary (acquired) drug resistance and an alarming proportion of virologic failure among patients under treatment, unveiling suboptimal access to antiretroviral therapy (ARV), low ARV adherence and dissemination of drug resistant HIV strains in primary infections. Our results call for immediate actions of public authority to implement preventive measures, serological screening and, for HIV-seropositive subjects, clinical and treatment follow-up in order to control HIV infection and limit the spread of drug resistance strains in Brazilian prisons.

Associated Data

GENBANK | KC286150; KC286151; KC286152; KC286153; KC286154; KC286155; KC286156; KC286157; KC286158; KC286159; KC286160; KC286161; KC286162; KC286163; KC286164; KC286165; KC286166; KC286167; KC286168; KC286169; KC286170; KC286171; KC286172; KC286173; KC286174; KC286175; KC286176; KC286177; KC286178; KC286179; KC286180; KC286181; KC286182; KC286183; KC286184; KC286185; KC286186; KC286187; KC286188; KC286189; KC286190; KC286191; KC286192; KC286193; KC286194; KC286195; KC286196; KC286197; KC286198; KC286199; KC286200; KC286201; KC286202; KC286203; KC286204; KC286205; KC286206; KC286207; KC286208; KC286209; KC286210; KC286211; KC286212; KC286213; KC286214; KC286215; KC286216; KC286217; KC286218; KC286219; KC286220; KC286221; KC286222; KC286223; KC286224; KC286225; KC286226; KC286227; KC286228; KC286229; KC286230; KC286231; KC286232; KC286233; KC286234; KC286235; KC286236; KC286237; KC286238; KC286239; KC286240; KC286241; KC286242; KC286243; KC286244; KC286245; KC286246; KC286247; KC286248; KC286249; KC286250; KC286251; KC286252; KC286253; KC286254; KC286255; KC286256; KC286257; KC286258; KC286259; KC286260; KC286261; KC286262; KC286263; KC286264; KC286265; KC286266; KC286267; KC286268; KC286269; KC286270; KC286271; KC286272; KC286273; KC286274; KC286275; KC286276; KC286277; KC286278; KC286279; KC286280; KC286281; KC286282; KC286283; KC286284; KC286285; KC286286; KC286287; KC286288; KC286289; KC286290; KC286291; KC286292; KC286293; KC286294; KC286295; KC286296; KC286297; KC286298; KC286299; KC286300; KC286301; KC286302; KC286303; KC286304; KC286305; KC286306; KC286307; KC286308; KC286309; KC286310; KC286311; KC286312; KC286313; KC286314; KC286315; KC286316; KC286317; KC286318; KC286319; KC286320; KC286321; KC286322; KC286323; KC286324; KC286325; KC286326; KC286327; KC286328; KC286329; KC286330; KC286331; KC286332; KC286333; KC286334; KC286335; KC286336; KC286337; KC286338; KC286339; KC286340; KC286341; KC286342; KC286343; KC286344; KC286345; KC286346; KC286347; KC286348; KC286349; KC286350; KC286351; KC286352; KC286353; KC286354; KC286355; KC286356; KC286357; KC286358; KC286359; KC286360; KC286361; KC286362; KC286363; KC286364; KC286365; KC286366; KC286367; KC286368; KC286369; KC286370; KC286371; KC286372; KC286373; KC286374; KC286375; KC286376; KC286377; KC286378; KC286379; KC286380; KC286381; KC286382; KC286383; KC286384; KC286385; KC286386; KC286387; KC286388; KC286389; KC286390; KC286391; KC286392; KC286393; KC286394; KC286395; KC286396; KC286397; KC286398; KC286399; KC286400; KC286401; KC286402; KC286403; KC286404; KC286405; KC286406; KC286407; KC286408; KC286409; KC286410; KC286411; KC286412; KC286413; KC286414; KC286415; KC286416; KC286417; KC286418; KC286419; KC286420; KC286421; KC286422; KC286423; KC286424; KC286425; KC286426; KC286427; KC286428; KC286429; KC286430; KC286431; KC286432; KC286433; KC286434; KC286435; KC286436; KC286437; KC286438; KC286439; KC286440; KC286441; KC286442; KC286443; KC286444; KC286445; KC286446; KC286447; KC286448; KC286449; KC286450; KC286451; KC286452; KC286453; KC286454; KC286455; KC286456; KC286457; KC286458; KC286459; KC286460; KC286461; KC286462; KC286463; KC286464; KC286465; KC286466; KC286467; KC286468; KC286469; KC286470; KC286471; KC286472; KC286473; KC286474; KC286475; KC286476; KC286477; KC286478; KC286479; KC286480; KC286481; KC286482; KC286483; KC286484; KC286485

References

  1. Braz J Med Biol Res. 2004 May;37(5):771-6 [PMID: 15107941]
  2. Lancet Infect Dis. 2007 Jan;7(1):32-41 [PMID: 17182342]
  3. PLoS Med. 2007 Dec;4(12):e339 [PMID: 18052602]
  4. AIDS. 2008 Oct 1;22(15):1993-2000 [PMID: 18753928]
  5. PLoS One. 2012;7(4):e35649 [PMID: 22530062]
  6. J Clin Virol. 2011 Jul;51(3):186-91 [PMID: 21622023]
  7. J Virol. 2009 Sep;83(17):8502-13 [PMID: 19553318]
  8. J Biol Chem. 2008 Aug 8;283(32):22222-32 [PMID: 18547911]
  9. J Med Virol. 2011 Oct;83(10):1682-8 [PMID: 21837783]
  10. J Antimicrob Chemother. 2011 Apr;66(4):702-8 [PMID: 21393163]
  11. Syst Biol. 2006 Aug;55(4):539-52 [PMID: 16785212]
  12. PLoS One. 2008 Mar 12;3(3):e1781 [PMID: 18335052]
  13. J Acquir Immune Defic Syndr. 2003 Dec 15;34(5):520-6 [PMID: 14657764]
  14. AIDS Res Treat. 2011;2011:154945 [PMID: 22162803]
  15. Int J Tuberc Lung Dis. 2005 Jun;9(6):633-9 [PMID: 15971390]
  16. Rev Saude Publica. 2000 Oct;34(5):431-6 [PMID: 11105105]
  17. BMC Evol Biol. 2006 Mar 24;6:29 [PMID: 16563161]
  18. AIDS Res Hum Retroviruses. 2009 Dec;25(12):1339-44 [PMID: 19954300]
  19. J Virol. 2007 Aug;81(15):7852-9 [PMID: 17507476]
  20. J Clin Virol. 2012 May;54(1):36-41 [PMID: 22326760]
  21. AIDS. 2005 Oct;19 Suppl 4:S81-6 [PMID: 16249660]
  22. AIDS. 2008 Oct 1;22(15):2001-11 [PMID: 18784462]
  23. J Acquir Immune Defic Syndr. 2007 Jul 1;45(3):328-33 [PMID: 17496564]
  24. J Virol. 1999 Jan;73(1):152-60 [PMID: 9847317]
  25. Braz J Infect Dis. 2001 Jun;5(3):111-8 [PMID: 11506773]
  26. Mol Biol Evol. 2011 Oct;28(10):2731-9 [PMID: 21546353]
  27. Science. 2000 Apr 7;288(5463):55-6 [PMID: 10766634]
  28. J Clin Virol. 2010 Jul;48(3):173-9 [PMID: 20483657]
  29. AIDS Res Hum Retroviruses. 2007 Dec;23(12):1579-86 [PMID: 18160017]
  30. Cad Saude Publica. 2001 Nov-Dec;17(6):1473-80 [PMID: 11784908]
  31. Virology. 2013 Jan 20;435(2):433-41 [PMID: 23068886]
  32. AIDS Res Hum Retroviruses. 2011 Dec;27(12):1349-53 [PMID: 21732793]
  33. Microbes Infect. 2010 Dec;12(14-15):1170-7 [PMID: 20713171]
  34. J Acquir Immune Defic Syndr. 2010 Jun;54(2):160-6 [PMID: 20130473]
  35. J Clin Virol. 2011 Dec;52(4):373-6 [PMID: 21975076]
  36. Cad Saude Publica. 2007 Sep;23(9):2197-204 [PMID: 17700954]
  37. J Acquir Immune Defic Syndr. 2012 Feb 1;59(2):185-93 [PMID: 22227488]
  38. Top Antivir Med. 2011 Nov;19(4):156-64 [PMID: 22156218]
  39. Syst Biol. 2010 May;59(3):307-21 [PMID: 20525638]

MeSH Term

Adult
Anti-HIV Agents
Brazil
Cluster Analysis
Comorbidity
Cross-Sectional Studies
Drug Resistance, Viral
HIV Infections
HIV-1
Humans
Molecular Sequence Data
Phylogeny
Prevalence
Prisons
pol Gene Products, Human Immunodeficiency Virus

Chemicals

Anti-HIV Agents
pol Gene Products, Human Immunodeficiency Virus

Word Cloud

Created with Highcharts 10.0.0HIVdruginfectionresistancetransmissioninmatessouthernBrazilmolecularHIV-1prisonshumanimmunodeficiencyvirusexposureuse667HIV-seropositiveclusterssubtypespopulationhighanalysisprimarytreatmentARVstrainsPeopledeprivedlibertyhigherriskdueincreasedintravenousunprotectedsexualactivitytattooingprisonbloodfightsrebellionsYetcontributionintramuralepidemicscarcelyknownespeciallylow-middle-incomesettingsstudysurveyed1incarceratedPresídioCentraldePortoAlegrelocatedcharacterizationseroprevalence66%110/1analysescarried40assesswithinfacilityphylogenetictechniquesepidemiologyobservedsimilaronereportedgeneralpredominanceCBCRF31_BCuniqueBCrecombinantsparticularrate24%URF_BCfoundmayreflectmultipleexposuresinvestigatedfailedfindHIV-infectedsharingImportantlypolgenomicfragmentsevidencedratessecondaryacquiredalarmingproportionvirologicfailureamongpatientsunveilingsuboptimalaccessantiretroviraltherapylowadherencedisseminationresistantinfectionsresultscallimmediateactionspublicauthorityimplementpreventivemeasuresserologicalscreeningsubjectsclinicalfollow-upordercontrollimitspreadBrazilianbehindbars:clusterreferencecorrectionalunit

Similar Articles

Cited By (9)